Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study

2008 ◽  
Vol 23 (8) ◽  
pp. 1130-1136 ◽  
Author(s):  
Pedro J. García Ruiz ◽  
Ángel Sesar Ignacio ◽  
Begoña Ares Pensado ◽  
Alfonso Castro García ◽  
Fernando Alonso Frech ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multicenter Study ◽  
Motor Fluctuations ◽  
Advanced Parkinson’S Disease ◽  
Subcutaneous Apomorphine

scholarly journals Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Bruna Meira ◽  
Bertrand Degos ◽  
Elise Corsetti ◽  
Mohamed Doulazmi ◽  
Emeline Berthelot ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Real Life ◽  
Routine Care ◽  
Motor Fluctuations ◽  
Psychological Status ◽  
Long Term Effects ◽  
Good Tolerability ◽  
Advanced Parkinson’S Disease

AbstractLong-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from consecutive advanced Parkinson’s disease patients treated in routine care were retrospectively collected over 24 months after CSAI initiation, with a focus on the 39-item Parkinson’s disease questionnaire (PDQ-39). We determined predictors of CSAI discontinuation and HRQoL improvement using multiple regression analysis. Of the 110 subjects evaluated over a 2-year period, 35% discontinued CSAI. Of those who continued treatment, HRQoL remained stable with a sustained reduction in motor fluctuations. The observed effect on dyskinesias was mild and transient. Of note, patients with preexisting impulse control disorders showed an overall good tolerability. PDQ-39 was the only baseline predictor of HRQoL improvement after 2 years of treatment. The presence of dyskinesias, poorer psychological status, shorter disease duration, male sex, and worse OFF state were predictors of discontinuation. Best candidates for CSAI are patients with: (i) poor baseline HRQoL and (ii) marked motor fluctuations.

Long term follow-up in advanced Parkinson’s disease treated with DBS of the subthalamic nucleus

2021 ◽  
Author(s):  
Maria Antonietta Volonté ◽  
Giacomo Clarizio ◽  
Sebastiano Galantucci ◽  
Pietro Giuseppe Scamarcia ◽  
Rosalinda Cardamone ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subthalamic Nucleus ◽  
Advanced Parkinson’S Disease ◽  
Long Term Follow Up

Long-term detection of motor fluctuations by wrist-worn sensors in Parkinson's disease

Basal Ganglia ◽  
2017 ◽  
Vol 8 ◽  
pp. 22
Author(s):  
Daniel Pichler ◽  
Urban Fietzek ◽  
Franz Pfister ◽  
Ahmad Ahmadi ◽  
Felix Achilles ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Fluctuations

Risperidone in levodopa-induced psychosis in advanced parkinson's disease: An open-label, long-term study

1997 ◽  
Vol 12 (4) ◽  
pp. 610-612 ◽  
Author(s):  
Giuseppe Meco ◽  
Andrea Alessandri ◽  
Patrizia Giustini ◽  
Vincenzo Bonifati
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Open Label ◽  
Term Study ◽  
Advanced Parkinson’S Disease ◽  
Long Term Study

scholarly journals A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice

2020 ◽  
Vol 10 (3) ◽  
pp. 176 ◽  
Author(s):  
Javier Pagonabarraga ◽  
José Matías Arbelo ◽  
Francisco Grandas ◽  
Maria-Rosario Luquin ◽  
Pablo Martínez Martín ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Practice ◽  
Motor Fluctuations ◽  
Adjunctive Treatment ◽  
Good Tolerability ◽  
Time Control ◽  
Clinical Scenarios ◽  
Off Time

Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson’s disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety.

Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease

2010 ◽  
Vol 25 (5) ◽  
pp. 578-586 ◽  
Author(s):  
Elena Moro ◽  
Andres M. Lozano ◽  
Pierre Pollak ◽  
Yves Agid ◽  
Stig Rehncrona ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multicenter Study ◽  
Long Term Results ◽  
Pallidal Stimulation
Sign in / Sign up

Export Citation Format

Share Document